New Facebook Group – ‘TreatSMA‘s Professional Therapy Group’

TreatSMA have launched a new Facebook group called TreatSMA‘s Professional Therapy Group.

This is a group for all Therapy Professionals, such as Physiotherapists, Occupational Therapists and Speech and Language Therapists, that have associations with SMA. It is a closed group and strictly confidential, with patients/parents permission Therapy Professionals can enclose descriptions, videos and photos to discuss treatments and ideas with each other. Please reach out to your/your child’s therapists and share the link with them so they can join, share and also learn. This group is worldwide so physios can unite and move forward by bringing new ideas and ways to the table.

If you are a Therapy Professional and would like to join you can do so here. Please note you must answer the membership questions and agree to the group rules to be accepted. The admin team of the group reserve the right to remove any post not felt to be in keeping with the aims of the group or supporting the ethos of TreatSMA.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more